Charles River Provides Translational Expertise at Neuroscience 2024
“Charles River is committed to changing the course of neuroscience research,” said
Partner with World-Class Scientists
Significant advances in genetics, pathology, biomarkers, and endpoints are driving momentum in neuroscience drug discovery, from small molecules to advanced therapies. Throughout the conference, Charles River experts will present posters and host discussions on the latest developments in neuroscience research and innovative approaches to tackling neurodegenerative disorders. Highlights include:
-
Establishment and validation of an in vitro co-culture model to study myelination using human iPSC-derived glutamatergic neurons and oligodendrocytes (Presented by Malika Bsibsi:
Sunday, October 6, 2024 ,4:00-5:00 p.m. CDT ) -
An iPSC derived neuroinflammation in vitro model of neurons and glial cells (Presented by Malika Bsibsi:
Monday, October 7, 2024 ,2:00-3:00 p.m. CDT )
Building Collective Momentum
On
Charles River’s global team of nearly 200 neuroscientists work across drug discovery and development, from basic research to regulatory approval, providing the translational science, range of services, and collaborative approach needed to discover novel therapies. Since 2018, Charles River has supported 80 percent of new neuroscience drugs approved by the
Charles River’s end-to-end approach to neurodegenerative disease is evidenced by several recent announcements, including the Company’s strategic collaboration with CEBINA to advance cutting edge neuroscience research, and the integration of Insightec’s novel low-frequency ultrasound platform, allowing precise therapeutic delivery of a variety of drugs, including delivery to deep brain structures. Additionally, Logica®, an Artificial Intelligence (AI) powered end-to-end drug discovery solution that translates biological insights into optimized preclinical candidates by leveraging the integration of Valo Health’s AI-powered Opal Computational Platform™ and Charles River’s leading expertise in drug discovery and preclinical development, recently announced an agreement with H. Lundbeck A/S (Lundbeck), utilizing Logica® to progress critical brain disease research.
A full schedule of Charles River’s activities during Neuroscience 2024 is available online. Additionally, experts will be available at Booth #417 for meetings with those interested in discussing neuroscience research and drug discovery.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003547119/en/
Investor:
Corporate Vice President, Investor Relations
781-222-6455
todd.spencer@crl.com
Media:
Corporate Vice President, Public Relations
781-222-6168
amy.cianciaruso@crl.com
Source: